Record-Breaking Financial Performance
In 2024, Tarsus reported more than $180 million in net product sales for XDEMVY, with over 163,000 bottles delivered to patients.
Expanded Sales Force and Coverage
The sales force was expanded from 100 to 150 representatives, leading to more than 15,000 eye care physicians prescribing XDEMVY. Coverage now extends to over 90% of potential patient lives.
Positive Pipeline Developments
Significant progress in advancing the pipeline, including plans for a Phase 2 trial of TP-04 for Ocular Rosacea and a clear regulatory path for TP-05 in Lyme disease prevention.
Successful Direct-to-Consumer Campaign
The launch of a direct-to-consumer advertising campaign, including network TV placements, has generated increased patient engagement and visits to eye care professionals.
High Gross Margins
Tarsus reported gross margins of approximately 93%, showcasing effective cost management alongside strong sales performance.